Tag: subscription

Binaural beat-based audio suite supports focus, rest, and digital clarity with a non-invasive, non-clinical format—now updated for 2025.

Bioma’s transparency-driven formula highlights XOS prebiotics, targeted Bifidobacterium strains, and tributyrin postbiotics—meeting rising consumer demand for non-synthetic gut health support without promotional claims.

In this 2025 forecast update, Wealth Megatrends, in collaboration with Weiss Ratings, offers unique insights into gold's continued upward trajectory. The release outlines Sean Brodrick's updated projection of $6,900 gold, framed within rising central bank demand, ongoing monetary volatility, and long-term shifts in asset preservation behavior. This analysis offers a distinct perspective on how this cycle compares to prior periods of financial instability and why mining equities are again drawing interest as part of a broader conversation on gold's role in today's evolving macroeconomic environment.

The global robotic surgery market size is calculated at USD 13.79 billion in 2025 and is expected to reach around USD 54.66 billion by 2034, growing at a CAGR of 16.54% for the forecasted period.

BOCA RATON, FL, July 03, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”) the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), announced today the purchase of 17,760 Solana (“SOL”) at an average purchase price of $153.10 and valued at approximately $2.72 million. Following the transaction, DeFi Development Corp. now holds a total of approximately 640,585 SOL and SOL equivalents, valued at approximately $98.1 million, inclusive of staking rewards.

FORM 8.5 (EPT/RI)

MONTREAL, July 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that it has entered into a binding arrangement agreement with CB Biotechnology, LLC (the “Purchaser”), an affiliate of Future Pak, LLC (“Future Pak”), a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products, whereby the Purchaser will acquire all the issued and outstanding common shares of the Company for US$3.01 per share in cash plus one contingent value right (“CVR”) per share for additional aggregate cash payments of up to US$1.19 per CVR if certain milestones as described below are achieved (the “Transaction”). The total Transaction consideration, assuming full payment of the CVRs, is US$254 million.